SCM
BPMC

Silverarc Capital Management’s Blueprint Medicines BPMC Stock Holding History

Silverarc Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,345
Closed -$3.31M – 70
2025
Q1 		$3.31M Buy
+37,345
New +$3.64M 0.68% 41

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Silverarc Capital Management's BPMC Position: Q2 2025 in Review

Silverarc Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 37,345 shares — an estimated $3.31M sold.

Silverarc Capital Management first reported a position in BPMC in Q1 2025 and held it in 1 quarter. The position peaked at $3.31M in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Silverarc Capital Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 37,345 Blueprint Medicines shares in Q2 2025, an estimated $3.31M.
  • Silverarc Capital Management first reported a position in Blueprint Medicines in Q1 2025 and held it in 1 quarter.
  • Silverarc Capital Management's Blueprint Medicines position peaked at $3.31M in Q1 2025.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.